publication . Article . Other literature type . 2018

IFN-γ and IL-5 whole blood response directed against mycolactone polyketide synthase domains in patients with Mycobacterium ulcerans infection.

Timothy Stinear; Richard Phillips; JUSTICE KOFI BOAKYE-APPIAH; Mathias Dongyele; Sacha Pidot; Aloysius Loglo; Michael Frimpong;
Open Access English
  • Published: 31 Jul 2018 Journal: PeerJ, volume 6 (eissn: 2167-8359, Copyright policy)
  • Publisher: PeerJ Inc.
  • Country: United Kingdom
Abstract
<jats:sec><jats:title>Background</jats:title><jats:p>Buruli ulcer is a disease of the skin and soft tissues caused by infection with a slow growing pathogen,<jats:italic>Mycobacterium ulcerans</jats:italic>. A vaccine for this disease is not available but<jats:italic>M. ulcerans</jats:italic>possesses a giant plasmid pMUM001 that harbours the polyketide synthase (PKS) genes encoding a multi-enzyme complex needed for the production of its unique lipid toxin called mycolactone, which is central to the pathogenesis of Buruli ulcer. We have studied the immunogenicity of enzymatic domains in humans with<jats:italic>M. ulcerans</jats:italic>disease, their contacts, as...
Subjects
free text keywords: Microbiology, Immunology, Infectious Diseases, Mycobacterium ulcerans, Immune response, Polyketide synthase domains, Buruli ulcer, Medicine, R, General Biochemistry, Genetics and Molecular Biology, General Neuroscience, General Agricultural and Biological Sciences, General Medicine
Funded by
EC| BURULIVAC
Project
BURULIVAC
Identification and development of vaccine candidates for Buruli Ulcer Disease
  • Funder: European Commission (EC)
  • Project Code: 241500
  • Funding stream: FP7 | SP1 | HEALTH
,
RCUK| R Phillips, KNUST Ghana. Pathogenesis and management of M. ulcerans disease, Buruli ulcer
Project
  • Funder: Research Council UK (RCUK)
  • Project Code: MR/J01477X/1
  • Funding stream: MRC
36 references, page 1 of 3

Beissner, M, Symank, D, Phillips, RO, Amoako, YA, Awua-Boateng, NY, Sarfo, FS, Jansson, M, Huber, KL, Herbinger, KH, Battke, F, Loscher, T, Adjei, O, Bretzel, G. Detection of viable Mycobacterium ulcerans in clinical samples by a novel combined 16S rRNA reverse transcriptase/IS2404 real-time qPCR assay. PLOS Neglected Tropical Diseases. 2012; 6 (8) [OpenAIRE] [PubMed] [DOI]

Bibert, S, Bratschi, MW, Aboagye, SY, Collinet, E, Scherr, N, Yeboah-Manu, D, Beuret, C, Pluschke, G, Bochud, P-Y. Susceptibility to Mycobacterium ulcerans disease (Buruli ulcer) is associated with IFNG and iNOS gene polymorphisms. Frontiers in Microbiology. 2017; 8: 1903 [OpenAIRE] [PubMed] [DOI]

Boulkroun, S, Guenin-Mace, L, Thoulouze, MI, Monot, M, Merckx, A, Langsley, G, Bismuth, G, Di Bartolo, V, Demangel, C. Mycolactone suppresses T cell responsiveness by altering both early signaling and posttranslational events. Journal of Immunology. 2010; 184 (3): 1436-1444 [OpenAIRE] [DOI]

Clutterbuck, E, Hirst, E, Sanderson, C. Human interleukin-5 (IL-5) regulates the production of eosinophils. Blood. 1989; 73 (6): 1504-1512 [OpenAIRE] [PubMed]

Coutanceau, E, Decalf, J, Martino, A, Babon, A, Winter, N, Cole, ST, Albert, ML, Demangel, C. Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone. Journal of Experimental Medicine. 2007; 204 (6): 1395-1403 [OpenAIRE] [PubMed] [DOI]

Coutanceau, E, Legras, P, Marsollier, L, Reysset, G, Cole, ST, Demangel, C. Immunogenicity of Mycobacterium ulcerans Hsp65 and protective efficacy of a Mycobacterium leprae Hsp65-based DNA vaccine against Buruli ulcer. Microbes and Infection. 2006; 8 (8): 2075-2081 [OpenAIRE] [PubMed] [DOI]

Dangy, JP, Scherr, N, Gersbach, P, Hug, MN, Bieri, R, Bomio, C, Li, J, Huber, S, Altmann, KH, Pluschke, G. Antibody-mediated neutralization of the exotoxin Mycolactone, the main virulence factor produced by Mycobacterium ulcerans. PLOS Neglected Tropical Diseases. 2016; 10 (6) [OpenAIRE] [PubMed] [DOI]

Demangel, C, Stinear, TP, Cole, ST. Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans. Nature Reviews Microbiology. 2009; 7 (1): 50-60 [OpenAIRE] [PubMed] [DOI]

Gooding, TM, Johnson, PDR, Smith, M, Kemp, AS, Robins-Browne, RM. Cytokine profiles of patients infected with Mycobacterium ulcerans and unaffected household contacts. Infection and Immunity. 2002; 70 (10): 5562-5567 [OpenAIRE] [PubMed] [DOI]

Guenin-Mace, L, Carrette, F, Asperti-Boursin, F, Le Bon, A, Caleechurn, L, Di Bartolo, V, Fontanet, A, Bismuth, G, Demangel, C. Mycolactone impairs T cell homing by suppressing microRNA control of L-selectin expression. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108 (31): 12833-12838 [OpenAIRE] [PubMed] [DOI]

Hall, B, Simmonds, R. Pleiotropic molecular effects of the Mycobacterium ulcerans virulence factor mycolactone underlying the cell death and immunosuppression seen in Buruli ulcer. Biochemical Society Transactions. 2014; 42 (1): 177-183 [PubMed] [DOI]

Huygen, K. Prospects for vaccine development against Buruli disease. Expert Review of Vaccines. 2003; 2 (4): 561-569 [OpenAIRE] [PubMed] [DOI]

Marion, E, Eyangoh, S, Yeramian, E, Doannio, J, Landier, J, Aubry, J, Fontanet, A, Rogier, C, Cassisa, V, Cottin, J, Marot, A, Eveillard, M, Kamdem, Y, Legras, P, Deshayes, C, Saint-Andre, JP, Marsollier, L. Seasonal and regional dynamics of M. ulcerans transmission in environmental context: deciphering the role of water bugs as hosts and vectors. PLOS Neglected Tropical Diseases. 2010; 4 (7) [OpenAIRE] [PubMed] [DOI]

Merritt, RW, Walker, ED, Small, PLC, Wallace, JR, Johnson, PDR, Benbow, ME, Boakye, DA. Ecology and transmission of Buruli ulcer disease: a systematic review. PLOS Neglected Tropical Diseases. 2010; 4 (12) [OpenAIRE] [PubMed] [DOI]

Nackers, F, Dramaix, M, Johnson, RC, Zinsou, C, Robert, A, De Biurrun Bakedano, E, Glynn, JR, Portaels, F, Tonglet, R. BCG vaccine effectiveness against Buruli ulcer: a case-control study in Benin. American Journal of Tropical Medicine and Hygiene. 2006; 75 (4): 768-774 [OpenAIRE] [PubMed]

36 references, page 1 of 3
Related research
Abstract
<jats:sec><jats:title>Background</jats:title><jats:p>Buruli ulcer is a disease of the skin and soft tissues caused by infection with a slow growing pathogen,<jats:italic>Mycobacterium ulcerans</jats:italic>. A vaccine for this disease is not available but<jats:italic>M. ulcerans</jats:italic>possesses a giant plasmid pMUM001 that harbours the polyketide synthase (PKS) genes encoding a multi-enzyme complex needed for the production of its unique lipid toxin called mycolactone, which is central to the pathogenesis of Buruli ulcer. We have studied the immunogenicity of enzymatic domains in humans with<jats:italic>M. ulcerans</jats:italic>disease, their contacts, as...
Subjects
free text keywords: Microbiology, Immunology, Infectious Diseases, Mycobacterium ulcerans, Immune response, Polyketide synthase domains, Buruli ulcer, Medicine, R, General Biochemistry, Genetics and Molecular Biology, General Neuroscience, General Agricultural and Biological Sciences, General Medicine
Funded by
EC| BURULIVAC
Project
BURULIVAC
Identification and development of vaccine candidates for Buruli Ulcer Disease
  • Funder: European Commission (EC)
  • Project Code: 241500
  • Funding stream: FP7 | SP1 | HEALTH
,
RCUK| R Phillips, KNUST Ghana. Pathogenesis and management of M. ulcerans disease, Buruli ulcer
Project
  • Funder: Research Council UK (RCUK)
  • Project Code: MR/J01477X/1
  • Funding stream: MRC
36 references, page 1 of 3

Beissner, M, Symank, D, Phillips, RO, Amoako, YA, Awua-Boateng, NY, Sarfo, FS, Jansson, M, Huber, KL, Herbinger, KH, Battke, F, Loscher, T, Adjei, O, Bretzel, G. Detection of viable Mycobacterium ulcerans in clinical samples by a novel combined 16S rRNA reverse transcriptase/IS2404 real-time qPCR assay. PLOS Neglected Tropical Diseases. 2012; 6 (8) [OpenAIRE] [PubMed] [DOI]

Bibert, S, Bratschi, MW, Aboagye, SY, Collinet, E, Scherr, N, Yeboah-Manu, D, Beuret, C, Pluschke, G, Bochud, P-Y. Susceptibility to Mycobacterium ulcerans disease (Buruli ulcer) is associated with IFNG and iNOS gene polymorphisms. Frontiers in Microbiology. 2017; 8: 1903 [OpenAIRE] [PubMed] [DOI]

Boulkroun, S, Guenin-Mace, L, Thoulouze, MI, Monot, M, Merckx, A, Langsley, G, Bismuth, G, Di Bartolo, V, Demangel, C. Mycolactone suppresses T cell responsiveness by altering both early signaling and posttranslational events. Journal of Immunology. 2010; 184 (3): 1436-1444 [OpenAIRE] [DOI]

Clutterbuck, E, Hirst, E, Sanderson, C. Human interleukin-5 (IL-5) regulates the production of eosinophils. Blood. 1989; 73 (6): 1504-1512 [OpenAIRE] [PubMed]

Coutanceau, E, Decalf, J, Martino, A, Babon, A, Winter, N, Cole, ST, Albert, ML, Demangel, C. Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone. Journal of Experimental Medicine. 2007; 204 (6): 1395-1403 [OpenAIRE] [PubMed] [DOI]

Coutanceau, E, Legras, P, Marsollier, L, Reysset, G, Cole, ST, Demangel, C. Immunogenicity of Mycobacterium ulcerans Hsp65 and protective efficacy of a Mycobacterium leprae Hsp65-based DNA vaccine against Buruli ulcer. Microbes and Infection. 2006; 8 (8): 2075-2081 [OpenAIRE] [PubMed] [DOI]

Dangy, JP, Scherr, N, Gersbach, P, Hug, MN, Bieri, R, Bomio, C, Li, J, Huber, S, Altmann, KH, Pluschke, G. Antibody-mediated neutralization of the exotoxin Mycolactone, the main virulence factor produced by Mycobacterium ulcerans. PLOS Neglected Tropical Diseases. 2016; 10 (6) [OpenAIRE] [PubMed] [DOI]

Demangel, C, Stinear, TP, Cole, ST. Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans. Nature Reviews Microbiology. 2009; 7 (1): 50-60 [OpenAIRE] [PubMed] [DOI]

Gooding, TM, Johnson, PDR, Smith, M, Kemp, AS, Robins-Browne, RM. Cytokine profiles of patients infected with Mycobacterium ulcerans and unaffected household contacts. Infection and Immunity. 2002; 70 (10): 5562-5567 [OpenAIRE] [PubMed] [DOI]

Guenin-Mace, L, Carrette, F, Asperti-Boursin, F, Le Bon, A, Caleechurn, L, Di Bartolo, V, Fontanet, A, Bismuth, G, Demangel, C. Mycolactone impairs T cell homing by suppressing microRNA control of L-selectin expression. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108 (31): 12833-12838 [OpenAIRE] [PubMed] [DOI]

Hall, B, Simmonds, R. Pleiotropic molecular effects of the Mycobacterium ulcerans virulence factor mycolactone underlying the cell death and immunosuppression seen in Buruli ulcer. Biochemical Society Transactions. 2014; 42 (1): 177-183 [PubMed] [DOI]

Huygen, K. Prospects for vaccine development against Buruli disease. Expert Review of Vaccines. 2003; 2 (4): 561-569 [OpenAIRE] [PubMed] [DOI]

Marion, E, Eyangoh, S, Yeramian, E, Doannio, J, Landier, J, Aubry, J, Fontanet, A, Rogier, C, Cassisa, V, Cottin, J, Marot, A, Eveillard, M, Kamdem, Y, Legras, P, Deshayes, C, Saint-Andre, JP, Marsollier, L. Seasonal and regional dynamics of M. ulcerans transmission in environmental context: deciphering the role of water bugs as hosts and vectors. PLOS Neglected Tropical Diseases. 2010; 4 (7) [OpenAIRE] [PubMed] [DOI]

Merritt, RW, Walker, ED, Small, PLC, Wallace, JR, Johnson, PDR, Benbow, ME, Boakye, DA. Ecology and transmission of Buruli ulcer disease: a systematic review. PLOS Neglected Tropical Diseases. 2010; 4 (12) [OpenAIRE] [PubMed] [DOI]

Nackers, F, Dramaix, M, Johnson, RC, Zinsou, C, Robert, A, De Biurrun Bakedano, E, Glynn, JR, Portaels, F, Tonglet, R. BCG vaccine effectiveness against Buruli ulcer: a case-control study in Benin. American Journal of Tropical Medicine and Hygiene. 2006; 75 (4): 768-774 [OpenAIRE] [PubMed]

36 references, page 1 of 3
Related research
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue